# Amlodipine

Drug · id `cardio:amlodipine` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Norvasc; Amlodipine besylate

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease  

## In plain language

Amlodipine is a calcium channel blocker taken by mouth. The US label read, for Norvasc, lists hypertension, to lower blood pressure, and coronary artery disease: chronic stable angina, confirmed or suspected vasospastic angina, and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, reducing the risk of hospitalization for angina and of a coronary revascularization procedure.

## Technical summary

RxNorm ingredient 17767; UNII 864V2Q084H. The label names the substance as amlodipine besylate, so UNII 864V2Q084H is the UNII of the salt form and is a broad match. MeSH descriptor D017311 is Amlodipine. Class: Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the NORVASC (amlodipine besylate), Viatris Specialty LLC label, effective 2023-02-15 in openFDA (application NDA019787). Other amlodipine labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of NORVASC (amlodipine besylate), in the Viatris Specialty LLC version dated 2023-02-15 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, to reduce the risk of hospitalization for angina and of a coronary revascularization procedure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227367289c-b0b0-466a-83e2-558e2985c29f%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-11-09T13:17:36Z. Source state: Current. Version fingerprint: bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227367289c-b0b0-466a-83e2-558e2985c29f%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:36Z. Source state: Current. Version fingerprint: bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d.
     How it applies: Effective date of the label text read, 20230215.

## Connected pages

- Amlodipine is a calcium channel blocker (FDA established pharmacologic class in RxClass): Calcium channel blockers (`cardio:calcium-channel-blockers`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-amlodipine-label-indications` and its context]
- FDA label lists the symptomatic treatment of chronic stable angina as an indication: Stable angina (`cardio:stable-angina`) [a claim, not a settled fact; see claim `cardio:claim-fda-amlodipine-label-indications` and its context]
- FDA label lists reducing the risk of hospitalization for angina and of coronary revascularization, in patients with angiographically documented coronary artery disease and without heart failure or an ejection fraction under 40%, as an indication: Coronary artery disease (`cardio:coronary-artery-disease`) [a claim, not a settled fact; see claim `cardio:claim-fda-amlodipine-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 16 registry products
- 40 registry trials

## Provenance

Content hash: de40f4c9407e82a5bc37f4afb4a95cc1b17df047422e5203f2f4ff6f7f9653a8
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
